Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Dealing

6 Sep 2013 13:58

RNS Number : 4334N
PuriCore Plc
06 September 2013
 



6 September 2013

PuriCore plc

("PuriCore" or the "Company")

 

Director Dealing

 

 

PuriCore (LSE: PURI), a global company focused on safely and effectively protecting people from the spread of infectious pathogens, today announces a director dealing, in accordance with the Disclosure and Transparency Rules. The Company announces that on the 5th and 6th September 2013, the following Director purchased shares in the Company, as set out below.

 

Name

Date purchased

Number of shares purchased

Purchase price of shares

Shareholding following the acquisition

% of issued share capital

Daniel Hegglin

Non-Executive Director

5 Sept 2013

6 Sept 2013

50,000

550,000

40p

43p

 

 

 

 

Total Dealing

600,000

 

3,909,091

 

7.80%

 

 

Enquiries:

UK

US

FTI Consulting

Sage Strategic Marketing

Susan Stuart

Jennifer Guinan

Victoria Foster Mitchell

+1 610.410.8111

+44 (0) 20 7831 3113

jennifer@sagestrat.com

 

About PuriCore

PuriCore plc (LSE: PURI) is a global company focused on safely and effectively protecting people from the spread of infectious pathogens without causing harm to human health or the environment. PuriCore's antimicrobial technology and complementary products are used principally in well-established core businesses and emerging sectors of two broad markets: Health Sciences and Food & Agriculture. In the Health Sciences market, PuriCore is the leading full provider of all products and services required for a safe, efficient, and compliant endoscope decontamination to protect patients in UK hospitals. PuriCore's breakthrough wound therapy solution is used to treat chronic and acute wounds including diabetic ulcers and burns as well as atopic dermatitis as dermatologic treatment products. In the Food & Agriculture market, PuriCore's portfolio provide savings to supermarket retailers in labour costs and improvements in inventory loss as well as address the issue of cross contamination of fresh produce and floral products. In addition, the Company is progressing in its research and development programmes in the UK on the use of its technology as an agricultural fungicide. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK. To receive additional information on PuriCore, visit www.puricore.com.

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSUGUQABUPWGPQ
Date   Source Headline
21st Nov 20177:00 amRNSRealm: Preclinical Data on PR022 Published
17th Nov 20177:00 amRNSDirectorate Change
2nd Nov 20177:00 amRNSRealm Therapeutics to Present at BIO-Europe® 2017
30th Oct 20177:00 amRNSRealm Presents Data at ACAAI Scientific Meeting
18th Oct 20177:00 amRNSHolding(s) in Company
18th Oct 20177:00 amRNSBlock Listing Application
17th Oct 20176:28 pmRNSHolding(s) in Company
16th Oct 20173:39 pmRNSHolding(s) in Company
16th Oct 20177:00 amRNSRealm Therapeutics to speak at BIO Investor Forum
13th Oct 20172:20 pmRNSHolding(s) in Company
13th Oct 20172:17 pmRNSHolding(s) in Company
12th Oct 20175:48 pmRNSHolding(s) in Company
12th Oct 20173:07 pmRNSRealm Therapeutics: Completion of £19.3m Placing
12th Oct 201711:04 amRNSHolding(s) in Company
12th Oct 201710:58 amRNSHolding(s) in Company
9th Oct 201711:35 amRNSResult of General Meeting
22nd Sep 20177:00 amRNSProposed Placing to raise £19.3 million
22nd Sep 20177:00 amRNSInterim Results
21st Sep 20176:01 pmRNSProposed Placing to raise £19.3 million
21st Sep 20176:00 pmRNSInterim Results
11th Sep 20177:00 amRNSFDA Permits PR013 to Proceed to Phase II Trial
7th Sep 20177:00 amRNSConference Presentation
18th Aug 20177:00 amRNSBlock listing Interim Review
2nd Aug 20177:00 amRNSSubmission of Investigational New Drug Application
6th Jul 20177:00 amRNSPresentation at World Congress on Inflammation
14th Jun 20177:09 amRNSPresentation at 2017 Marcum Microcap Conference
6th Jun 201711:05 amRNSResult of AGM
11th May 201712:21 pmRNSNotice of AGM
23rd Mar 20172:57 pmRNSAnnual Report and Accounts Available
23rd Mar 20177:00 amRNSFinal Results and Business Update
6th Mar 20177:00 amRNSConference Presentation
28th Feb 20177:00 amRNSFDA permits PR022 to Proceed to Phase 2 Trial
20th Feb 20177:00 amRNSBlock listing Interim Review
13th Feb 20177:00 amRNSPresentation at BIO CEO & Investor Conference
30th Jan 20177:00 amRNSResearch Update - Submission of first IND
5th Jan 20177:00 amRNSConference Presentations
4th Jan 20177:00 amRNSGrant of Options
21st Dec 20167:00 amRNSPDMR dealing
16th Dec 20167:00 amRNSIvan Gergel appointed as Non-Executive Director
7th Dec 20167:00 amRNSChange of name to Realm Therapeutics
18th Nov 20167:00 amRNSGrant of Options
17th Nov 20167:00 amRNSHolding(s) in Company
16th Nov 20167:00 amRNSDevelopment Programmes Update & Company Renaming
10th Oct 20167:00 amRNSCompletion of Supermarket Retail Business Disposal
7th Oct 20165:52 pmRNSCompletion of Supermarket Retail Business Disposal
6th Oct 201611:43 amRNSResult of General Meeting
23rd Sep 20162:47 pmRNSDirector/PDMR Dealing
22nd Sep 20162:15 pmRNSGrant of Options
20th Sep 20167:00 amRNSProposed Disposal of Supermarket Retail Business
20th Sep 20167:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.